Comparative Pharmacology
Head-to-head clinical analysis: INVELTYS versus PRED G.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVELTYS versus PRED G.
INVELTYS vs PRED-G
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid; modulates inflammatory response by binding to glucocorticoid receptors, altering gene expression and suppressing pro-inflammatory cytokines.
Prednisolone acetate is a glucocorticoid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; gentamicin sulfate is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to 30S ribosomal subunit.
Instill 1 drop into the affected eye(s) four times daily for 14 days, then taper as clinically indicated.
1 drop of the ophthalmic suspension (containing prednisolone acetate 1% and gentamicin sulfate 0.3%) into the affected eye(s) every 2-4 hours during the day, then taper as clinical signs improve. For severe disease, 1 drop every hour initially.
None Documented
None Documented
Approximately 1.5 hours (range 1-2 hours) for the ophthalmic suspension; terminal half-life in systemic circulation is about 3 hours after topical ocular administration.
The terminal elimination half-life of gentamicin (the active component) is approximately 2–3 hours in adults with normal renal function. In neonates, half-life is prolonged to 5–11 hours. The immunosuppressive component (prednisolone) has a half-life of 2–4 hours.
Primarily hepatic metabolism with minimal renal excretion (<5% unchanged in urine). Fecal elimination accounts for approximately 20% of the dose.
Renal excretion accounts for approximately 70% of elimination, with the remainder as unchanged drug in feces (20%) and biliary excretion (10%).
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Antibiotic Combination